Effect of age and race on pharmacokinetics of repurposed
COVID-19 drugs
Figure 2 shows the PBPK model simulated PK profiles for
different age brackets: 18 to 40 years, 40 to 65 years, and 65 to 98
years (geriatric population). This age brackets represented a typical
demographics from a recent remdesivir clinical trial [2]. The PBPK
model-based results are in line with observed data as shown inSupplementary Table 3 . Though geriatric population exhibited
higher exposure for all drugs compared to the age bracket of 18 to 40
years, but fell within 95% PI of healthy volunteers except for
dexamethasone, which is marginally outside the shaded area of 95% PI
(Figure 2A) . PBPK analysis suggests race has no clinically
meaningful effect on the clearance of all COVID-19 drugs, as the mean
simulated Chinese and Japanese population profiles fall within 95% PI
of Caucasian population (Figure 2B) Therefore, no dose
adjustment is required based on race.